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tively. Thus, conclusions from ICER and MDA assessments are consistent. To inves-
tigate the model robustness, we performed one-way and probabilistic sensitivity 
analyses. All sensitivity analyses illustrated that MDA dominated EIA and CA within 
the predefined ranges of input variables. ConClusions: Our study demonstrated 
that the routine use of MDA for CDI patients would result in substantial savings 
and improved health outcomes in US patients, compared to traditional diagnostic 
assays for this infection. These are the first data to evaluated QALY outcomes as 
they may vary with diagnostic test choice for CDI.
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Cost-EffECtIvENEss of BECaPlErmIN GEl oN WouNd ClosurE IN thE 
trEatmENt of PrEssurE ulCErs
Gilligan A.M., Waycaster C.
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA
objeCtives: Determine the cost-effectiveness of becaplermin gel* on wound heal-
ing for the treatment of pressure ulcers (PU). Methods: A 2-stage Markov model 
was used to predict expected costs and outcomes of wound healing for becaplermin 
gel once daily compared to placebo gel over a 1-year time period. Outcome data used 
in the analysis were derived from a 16-week randomized clinical trial. Primary out-
come of interest was ulcer-free weeks. A total of 61 patients completed the study; 31 
for becaplermin gel once-daily, and 30 for placebo gel. Patients in both arms received 
dressing changes twice daily. Patients in the treatment arm received becaplermin 
gel once daily followed by placebo gel. Transition probabilities for the Markov states 
were estimated from the clinical trial. Ulcer recurrence rates were derived from PU 
literature. Utilization for becaplermin gel was calculated using the manufacturer’s 
recommended dosing algorithm for diabetic foot ulcers. Costs were derived from 
standard cost references and medical supply wholesalers. The economic perspec-
tive taken was that of the payer. Results: Wound closure for patients treated with 
becaplermin gel was significantly (p< 0.01) higher compared to placebo gel (23% 
versus 0%, respectively) at 16 weeks. Over 1-year, patients treated with becaplermin 
gel had substantially higher ulcer-free weeks compared to placebo patients (13.5 
versus 0.0, respectively). Patients treated with becaplermin gel incurred higher total 
costs than those receiving placebo. Expected annual direct costs for PU were $3,234 
for becaplermin gel and $1,222 for placebo. The incremental cost-effectiveness ratio 
(ICER) was $149 (approximately $21/day), indicating that patients would have to pay 
an extra $149 to gain one additional ulcer-free week. ConClusions: Becaplermin 
gel was cost-effective over placebo, yielding better outcomes at a slightly higher 
cost. In addition, becaplermin gel is an effective treatment for wound healing and 
should be considered for use in the management of pressure ulcers. *Regranex®, 
Smith & Nephew Biotherapeutics, Fort Worth, Texas
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Cost EffECtIvENEss of ColIstImEthatE sodIum for thEraPy of 
INfECtIoNs CausEd By multIdruG-rEsIstaNt (mdr) IN mExICo
Rely K.1, Salinas G.E.2, Alexandre P.K.3
1CEAHT, Mexico, Mexico, 2Hospital Infantil de México Federico Gómez, Secretaría de Salud, 
Mexico, D.F., Mexico, 3Johns Hopkins University, Baltimore, MD, USA
objeCtives: To determine the cost effectiveness of colistimethate sodium for 
the treatment of infections caused by multidrug-resistant (MDR). Methods: We 
compare key outcomes related to survival, infection averted and costs for infec-
tions caused by MDR. A lifetime Markov model was used to estimate the expected 
outcomes and costs for patients treated with colistimethate sodium vs non- colis-
timethate sodium group. Colistimethate sodium at a dosage of 5mg/kg/day was 
given intravenously in two divided doses. Primary outcomes were the clinical 
response and 30-day mortality; secondary outcomes were microbiological response 
and adverse events. The cost-effective analysis was conducted from the Mexican 
Health care perspective. Costs were derived from the literature, future costs and 
effects were discounted at 5% per recommendations for analyses in Mexico. All 
costs are presented in 2013 US dollars. Multiple 1-way and Probabilistic sensitivity 
analyses were performed. Results: In the colistimethate sodium group, 80.8% 
had a favorable clinical response, the overall mortality of the patients in the colis-
timethate sodium group was 46.2% and that in the non- colistimethate sodium 
group was 80%. Nephrotoxicity was found in 30.8% in the colistimethate sodium 
group. The model projects an accumulated discounted cost to the Mexican health 
care system per patient receiving the Colistimethate sodium regimen of $8,525 
compared to $7,384 for non- colistimethate sodium regimen. The base-case analy-
sis presented incremental cost-effectiveness ratios for colistimethate sodium vs 
non- colistimethate sodium grup of $ 2,213 per LYG. These values are in accordance 
with the recommendations of the Commission on Macroeconomics and Health, 
WHO, suggesting that health technologies with ICERs below the per capita GDP are 
considered very cost-effective. Results were robust to various assumptions tested 
in the sensitivity analysis. ConClusions: This study suggest that in the Mexican 
setting, use of non- colistimethate sodium for treatment of infections caused by 
MDR is likely to be cost effective.
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Cost-EffECtIvENEss aNalysIs of mICafuNGIN vErsus CasPofuNGIN IN 
thE trEatmENt of INvasIvE CaNdIda INfECtIoN IN ChINa
Wang C, Dong H., Sun L.
Shenyang Pharmaceutical University, Shenyang, China
objeCtives: To evaluate the cost-effectiveness of micafungin compared to caspo-
fungin in the treatment of invasive Candida infection in China. Methods: A deci-
sion-tree model was developed to estimate the cost-effectiveness of micafungin and 
caspofungin from the perspective of the whole society. In the model, outcome on 
effectiveness was derived from an international, randomized, double-blind, phase III 
clinic trial and cost data was based on China’s practical situation. In the sensitivity 
analysis we use relative measurement method and absolute measurement method 
to analyze the results. Results: At the end of all antifungal therapy, the treat-
ment success rate of micafungin 100 mg/d group, micafungin 150 mg/d group and 
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mICafuNGIN vErsus CasPofuNGIN for thE trEatmENt of systEmIC 
CaNdIda INfECtIoNs: a Cost-EffECtIvENEss aNalysIs for sWItzErlaNd
Felder S.1, Mayrhofer T.2
1University of Basel, Basel, Switzerland, 2University of Duisburg-Essen, Essen, Germany
objeCtives: Comparing the cost-effectiveness of Micafungin and Caspofungin for 
the treatment of systemic candida infections (including invasive candidiasis and 
candidaemia) in Switzerland. Methods: To this end, a health economic decision 
model, based on a phase-III double-blind RCT with global patient data is used. 
Hospitalization and primary medication costs are based on official Swiss data. The 
effectiveness outcome is defined as successfully treated and alive patients at the 
end of the study period. To test for robustness of cost-effectiveness results, a sub-
group analysis, a two-way sensitivity analysis and a probabilistic sensitivity analysis 
(PSA) are performed. Results: The main analysis shows that 60 % of Micafungin 
patients were successfully treated and survived at the end of study compared to 
58 % of Caspofungin patients. The costs of a Micafungin treatment (CHF 54,503) 
are smaller than the costs of a Caspofungin treatment (CHF 56,704). This results in 
a lower cost-effectiveness ratio for Micafungin (CHF 91,356) than for Caspofungin 
(CHF 98,900). Moreover, Micafungin dominates Caspofungin in the incremental cost-
effectiveness analysis. For European patients only, who can be assumed to be a more 
homogenous group and a better approximation of Swiss patients, the cost-effective-
ness ratio for Micafungin is CHF 88,474 compared to CHF 105,202 for Caspofungin. 
Two-way sensitivity analyses for both, total sample and European sub-sample, 
render Micafungin more cost-effective than Caspofungin in 20 out of 20 scenarios 
(highest incremental cost-effectiveness for Micafungin amounts to CHF 16,382). 
Probabilistic sensitivity analysis shows similar findings. ConClusions: This 
study analyzes the cost-effectiveness of Micafungin as compared to Caspofungin 
for the treatment of systemic candida infections in Switzerland. Both lower costs 
and higher effectiveness of Micafungin render Micafungin as more cost-effective 
than Caspofungin.
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thE hEalth aNd ECoNomIC ImPaCt of vaCCINatIoN WIth 7-valENt 
PNEumoCoCCal vaCCINE (PCv7) durING aN aNNual INfluENza EPIdEmIC 
aNd INfluENza PaNdEmIC IN ChINa
Wang B.1, Caldwell R.2, Roberts C.S.3, An Z.4, Strutton D.R.5, Chen C.I.6
1Alliance Life Sciences, Somerset, NJ, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Pfizer 
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5Pfizer, Inc., Collegeville, PA, USA, 6Pfizer Inc., Beijing, China
objeCtives: China has experienced several severe outbreaks of influenza over the 
past century: 1918, 1957, 1968, and 2009. Influenza itself can be deadly; however, 
the increase in mortality during an influenza outbreak is also attributable to sec-
ondary bacterial infections, specifically pneumococcal disease. Given the history 
of pandemic outbreaks and the associated morbidity and mortality, we investigate 
the cost-effectiveness of a PCV7 vaccination program in China from the context of 
typical and pandemic influenza seasons. Methods: A decision-analytic model 
was employed to evaluate the impact of a 7-valent pneumococcal vaccine (PCV7) 
infant vaccination program on the incidence, mortality, and cost associated with 
pneumococcal disease during a typical influenza season and influenza pandemic in 
China. Estimates were performed comparing an 85% level of PCV7 coverage among 
all newborn infants during a single year in China relative to a case where no PCV7 
vaccinations occur for both a typical influenza season and a severe influenza pan-
demic in China. The model incorporates Chinese data where available and includes 
both direct and indirect (herd) effects on the unvaccinated population, assuming 
steady state. Costs were calculated using a payer perspective and included vac-
cination program costs and direct medical expenditures from pneumococcal dis-
ease. Results: The model predicts that PCV7 vaccination in China would prevent 
4,855,878 cases of pneumococcal disease and 66,351 deaths in a single year during a 
normal influenza season. The estimated incremental-cost-effectiveness ratios were 
¥24,383 per life-year saved and ¥25,519 per quality-adjusted-life-year gained. During 
an influenza pandemic, the model estimates that vaccination with PCV7 would 
prevent 8,192,158 cases of pneumococcal disease and 659,216 deaths, and would 
be cost-saving. ConClusions: Vaccination with PCV7 in China is cost-effective 
during typical influenza season. During an influenza pandemic, the benefit of PCV7 
in preventing excess pneumococcal morbidity and mortality renders a PCV7 vac-
cination program cost-saving.
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ECoNomICs aNalysIs of dIaGNostIC mEthods for ClostrIdIum 
dIffICIlE INfECtIoN
Ni W.1, Hay J.1, Zangwill K.M.2
1University of Southern California, Los Angeles, CA, USA, 2UCLA Center for Vaccine Research, 
Torrance, CA, USA
objeCtives: Several molecular diagnostic assays (MDA) are now commercially 
available for the diagnosis of Clostridium difficile infection (CDI). These assays detect 
genomic material associated with the pathogen’s toxin A, B and/or other genes in 
stool samples. Compared with the traditional CDI laboratory assay diagnostics, MDA 
has a shorter turn-around time and better sensitivity, but requires relatively expen-
sive instrumentation. The impact of routine use of MDA on the economics of CDI 
disease (via shorter hospitalization and less morbidity) is not clear. We evaluated 
whether routine use of MDA reduces the health care costs and improves quality-
adjusted life years (QALYs) for CDI patients. Methods: We performed a decision 
tree analysis to compare cost effectiveness of MBD with enzyme immunoassay 
(EIA) and cytotoxin assay (CA) respectively, using data from published literature 
and experts’ opinions. Analyses were conducted from the societal perspective. Both 
incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) were 
used as criteria for evaluation. Results: The ICER shows that MDA is dominant 
to the other two alternatives. Using a base willingness-to-pay per QALY threshold 
($150,000), the NMB of MDA vs. EIA and CA are around $4,000 and $1,500, respec-
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TDF/FTC+ATV/r, £85,477 for ABC/3TC+EFV, and £99,609 for ABC/3TC+ATV/r. At a will-
ingness-to-pay threshold of £30,000 per QALY gained, TDF/FTC-based regimens were 
predicted to be cost-effective compared with ABC/3TC-based regimens, with incre-
mental cost-effectiveness ratios of £20,545 for TDF/FTC+EFV versus ABC/3TC+EFV 
and £20,652 for TDF/FTC+ATV/r versus ABC/3TC+ATV/r. In subgroup analyses, TDF/
FTC-based regimens were predicted to yield more QALYs and to remain cost-effec-
tive compared with ABC/3TC-based regimens. ConClusions: In an analysis of 
the regimens examined in the ACTG 5202 clinical trial for treatment-naïve adults 
with HIV-1 infection, regimens containing TDF/FTC yielded more favorable health 
outcomes and were predicted to be cost-effective compared with regimens con-
taining ABC/3TC.
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Cost-EffECtIvENEss of ProtEasE INhIBItors for thE trEatmENt of 
ChroNIC hEPatItIs C INfECtIoN: a systEmatIC rEvIEW
Silva N.1, Espinoza M.A.2
1Universidad de Chile, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, Chile
objeCtives: The current recommendations for hepatitis C infection genotype 1 
include one protease inhibitor (IP), boceprevir or telaprevir, in addition to the pre-
vious standard dual therapy (DT) (peginterferon plus ribavirin). However, the cost 
of these new drugs imposes high financial burden in the health care systems. The 
aim of this study is to undertake a systematic review of the cost-effectiveness of 
boceprevir compared to telaprevir and DT. Methods: A systematic search was 
conducted in MEDLINE, EMBASE, Econlit and NHS-EED. Only full-text published 
manuscripts were considered and no further restriction were included. Relevant 
studies were selected by two independent researchers. Disagreements were resolved 
by discussion. A checklist was applied based on the CHEERS guideline to assess 
the quality of the studies. Results: Nine studies were found. Three compared 
Boceprevir versus DT whereas 6 compared both IP with DT. Six analyses were pre-
sented for naïve (no previously treated) patients and 5 analyses for patients previ-
ously treated. Comparators vary in terms of the schemes used and stopping rules 
applied. All studies modeled the disease properly. However, important differences 
in assumptions and parameters were found. Most studies adopted a national health 
system perspective. Only two studies used information from mixed treatment com-
parisons to be incorporated into the model. 8 out of 9 studies concluded that the IP 
is cost-effective for their corresponding jurisdiction. In naïve patients, two studies 
reported Telaprevir being cost-effective against Boceprevir and no study favored 
Boceprevir. In patients previously treated one study favors Boceprevir and two stud-
ies favors Telaprevir. ConClusions: The treatment with IP compared with DT is 
cost-effective in most jurisdictions where it has been evaluated. However, important 
variations were found in terms of patient´s subgroups and schemes of treatment. 
It cannot be concluded that one drug is more cost-effective than the other due to 
important structural uncertainty.
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Cost-mINImIzatIoN study of sEquENtIal thEraPy of lINEzolId IN a 
BrazIlIaN PuBlIC hosPItal: WhICh Is thE PharmaCoECoNomIC ImPaCt?
Taguti E., Silva E.A.A., Steimbach L.M., Sanches A.C.C.
State University of West Paraná, Cascavel, Brazil
objeCtives: Conduct a pharmacoeconomic analysis, cost-minimization type of 
therapy with linezolid in patients hospitalized between August, 2009 and December, 
2010 in a public hospital in Brazil. Methods: We conducted a retrospective cohort 
study at a Brazilian public hospital from August 1, 2009 through December 31, 2010. 
A cost-minimization analysis was undertaken for which patients used linezolid 
during the internment in this period, from the perspective of the Brazilian public 
health system. Results: The medical records of 61 patients were evaluated. Of all 
patients, 67.2% were male and mean age was 43.2 ± 17.8 years. The therapy with lin-
ezolid lasted 10.6 ± 4.7 days. The antibiogram was present in 65.6% of the records. In 
50.8% of cases, the bacteria were sensitive to linezolid. The main reason for the use 
of antibiotics was sepsis and nosocomial pneumonia (34.4% each). Sixteen (26.2%) 
patients met the criteria for changing the route of administration of the antimi-
crobial. Altogether, the cost of treatment with linezolid for these 16 patients was 
US$ 39.755,05. If it were adopted sequential therapy, the treatment would cost US$ 
31.744,28, which represents a saving of US$ 8.010,77 to the hospital. ConClusions: 
The results demonstrated the importance of pharmacoeconomic analysis of lin-
ezolid to the hospital, because in 17 months of cost analysis, these could have 
been reduced by 20,2% only with the switch antibiotic therapy. It is expected that 
results of studies such as this may contribute to the rational use of antimicrobials 
and resources for hospitals.
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ExPECtEd Cost-utIlIty of quadrIvalENt INfluENza vaCCINE uNdEr a 
uNIvErsal INfluENza ImmuNIzatIoN ProGram IN oNtarIo, CaNada
Roïz J.1, Chit A.2
1Creativ-Ceutical, London, UK, 2Sanofi Pasteur, Toronto, ON, Canada
objeCtives: Ontario, Canada, immunizes against influenza using a trivalent 
inactivated influenza vaccine (IIV3) under a Universal Influenza Immunization 
Program (UIIP). The UIIP offers IIV3 free of charge to all Ontarians over 6 months 
of age. A newly approved quadrivalent inactivated influenza vaccine (IIV4) offers 
wider protection against influenza B disease. In this study, we explore the expected 
cost-utility and budget impact of replacing IIV3 with IIV4 within the context of 
Ontario’s UIIP. Methods: We developed a model based on Ontario outcomes data 
published by Kwong and colleagues. We used Ontario based health care costs and 
Canadian based labor costs. Efficacy of IIV3 and IIV4 were estimated in a similar 
manner to a previous publication by Reed and colleagues. However, we improved 
by including emerging data from new meta-analyses on the efficacy of IIV3. These 
include new estimates of cross protection against mismatched B influenza offered 
by IIV3, as well as, new estimates of the vaccine efficacy in seniors. Conservatively, 
herd protection was not considered. Results: Over an average influenza season, 
caspofungin group were 74.9%,68.3%,70.2%, respectively; total costs were $8650.1, 
$10146.3, $9744.6, respectively. Thus, the cost-effectiveness ratio were 115.5, 148.6, 
138.8, respectively. ConClusions: Micafungin 100 mg/d group is the most cost-
effective option in the treatment of invasive Candida infection in China, followed 
by caspofungin group.
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ECoNomIC valuE of usING aNtImICroBIal CoatEd suturEs for 
aBdomINal INCIsIoNs to PrEvENt surGICal sItE INfECtIoNs
Singh A.1, Bartsch S.M.2, Muder R.R.3, Lee B.Y.2
1University of Pittsburgh, Pittsburgh, PA, 2Johns Hopkins Bloomberg School of Public Health, 
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objeCtives: Since surgical site infections (SSI) continue to impose a substantial 
burden to hospital and society, there is a need to evaluate newer SSI-prevention 
interventions such as antimicrobial (e.g., triclosan) coated sutures. Methods: We 
developed a decision analytic model using TreeAge Pro to determine the cost-effec-
tiveness of antimicrobial sutures in abdominal incisions from the hospital, third 
party payer, and societal perspectives. Sensitivity analyses systematically varied the 
risk of developing an SSI (range: 5% - 20%), cost of triclosan-coated sutures (range: $5 
- $25 per inch), and efficacy of triclosan-coated sutures to prevent infection (range: 
5% - 50%). Results: Depending on their efficacy, triclosan-coated sutures saved 
$4,109 – 13,975 (from the hospital perspective), $4,133 – 14,297 (third party payer), 
and $40,127 – 53,244 (societal) per SSI prevented, when a surgery had a 15% SSI risk. 
However, if the SSI risk after surgery was ≤ 5% and the efficacy in preventing SSIs 
was ≤ 10%, triclosan-coated sutures resulted in extra expenditure for hospitals and 
third party payers; resulting in extra costs of $1,626 and $1,071 per SSI prevented 
for hospitals and third party payers respectively, if SSI risk was 5% and efficacy was 
10%. ConClusions: Our results show that switching to triclosan-coated sutures 
from the uncoated sutures can prevent SSIs and save substantial costs to hospitals, 
third party payers, and society over a wide range of SSI prevention efficacy, cost, 
and risk values.
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Cost-EffECtIvENEss of quadrIvalENt INfluENza vaCCINatIoN ProGram 
for thE EldErly aGEd 65 yEars or oldEr IN taIWaN
Yang M.C., Tan C.H.
National Taiwan University, Taipei, Taiwan
objeCtives: Vaccines have been the main global means to minimize the impact of 
influenza and are recommended by WHO for individuals aged 65 years or older. The 
primary goal of influenza vaccination in the elderly is to reduce the risk of compli-
cations. Since 1998, a public-funded trivalent influenza vaccine (TIV) vaccination 
program has been implemented by the Taiwan government targeting people aged 
over 65 years. Another proposed alternative for preventing seasonal influenza is 
quadrivalent influenza vaccine (QIV) which contains two influenza A-lineages and 
two influenza B-lineages. The aim of the study is to assess, from the governmental 
perspective, the cost-effectiveness of adopting QIV versus TIV for the elderly aged 
65 years or older. Methods: A Markov model was used to estimate the cost and 
effectiveness of QIV and TIV in the elderly. Direct cost data was obtained from the 
Taiwan National Health Insurance claims data. Vaccine efficacy and coverage rate 
were based on government statistical reports. Outcomes of lifetime included cases, 
utilizations, and deaths avoided and QALYs gained. The corresponding incremental 
cost-effectiveness ratios (ICERs) were also estimated. The discount rate of cost and 
effectiveness was set at 3.5%. Results: Compared to TIV, adopting QIV would yield 
the influenza-related outcomes as follows: 26,319 influenza cases avoided, 26,021 
cases of outpatient visit avoided, 2,771 cases of influenza complication avoided, and 
330 deaths avoided. Using QIV instead of TIV would bring an additional 19,310,320 
QALYs at an extra cost of US$223.39 billion, yielding an ICER of US$35,851.3 per QALY 
gained. When herd protection of vaccination is considered, the ICER would reduce 
to US$32,660.1 per QALY gained. ConClusions: To use QIV as an alternative of 
first-line strategy to prevent seasonal influenza for the elderly in Taiwan would be 
cost-effectiveness from the governmental perspective.
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Cost-EffECtIvENEss aNalysIs of tENofovIr/EmtrICItaBINE aNd 
aBaCavIr/lamIvudINE IN ComBINatIoN WIth EfavIrENz or atazaNavIr/
rItoNavIr for trEatmENt-NaIvE adults WIth hIv-1 INfECtIoN IN thE 
uNItEd KINGdom
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objeCtives: To assess the cost-effectiveness of the four comparators examined 
in the ACTG 5202 clinical trial, tenofovir/emtricitabine (TDF/FTC) or abacavir/
lamivudine (ABC/3TC) in combination with efavirenz (EFV) or atazanavir/ritonavir 
(ATV/r), for treatment-naïve adults with HIV-1 infection in the United Kingdom 
(UK). Methods: A Markov model with six health states based on CD4+ cell-count 
ranges was developed to estimate costs and health outcomes for individuals on first-
line therapy. Head-to-head efficacy data (lack of regimen failure and mean CD4+ cell-
count changes) up to 192 weeks for TDF/FTC+EFV, TDF/FTC+ATV/r, ABC/3TC+EFV, 
and ABC/3TC+ATV/r were obtained from the ACTG 5202 clinical trial. Antiretroviral 
drug costs were based on current list prices. Utility values, mortality, and other 
direct medical costs (2012 UK pounds) were stratified by CD4+ cell-count range 
and obtained from published sources. All outcomes were discounted at 3.5% per 
year. Sensitivity and subgroup analyses were conducted, including analysis of low 
(< 100,000 copies/mL) and high (≥ 100,000 copies/mL) baseline viral load. Results: 
Individuals using TDF/FTC-based regimens were predicted to remain on first-line 
therapy longer and accrue more QALYs than individuals using ABC/3TC-based regi-
mens (QALYs: 6.30 for TDF/FTC+EFV, 6.45 for TDF/FTC+ATV/r, 5.02 for ABC/3TC+EFV, 
and 5.26 for ABC/3TC+ATV/r). Costs were £111,882 for TDF/FTC+EFV, £124,302 for 
